Compare BNL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | NUVB |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2020 | N/A |
| Metric | BNL | NUVB |
|---|---|---|
| Price | $18.64 | $6.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $19.75 | $10.44 |
| AVG Volume (30 Days) | 1.9M | ★ 6.3M |
| Earning Date | 02-18-2026 | 03-05-2026 |
| Dividend Yield | ★ 6.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $447,973,000.00 | $26,748,000.00 |
| Revenue This Year | $5.85 | $616.63 |
| Revenue Next Year | $7.00 | $202.59 |
| P/E Ratio | $39.81 | ★ N/A |
| Revenue Growth | 5.49 | ★ 1137.19 |
| 52 Week Low | $13.96 | $1.54 |
| 52 Week High | $18.87 | $9.75 |
| Indicator | BNL | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 31.51 |
| Support Level | $17.60 | $5.60 |
| Resistance Level | $18.32 | $6.63 |
| Average True Range (ATR) | 0.34 | 0.53 |
| MACD | 0.11 | -0.35 |
| Stochastic Oscillator | 92.06 | 14.35 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.